Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline

Clinical Therapeutics

Volumn 36, Issue 10, 2014, Pages 1317-1333

  Sakoulas, George ^a   Moise, Pamela A ^b   Casapao, Anthony M ^c   Nonejuie, Poochit ^a   Olson, Joshua ^a   Okumura, Cheryl Y M ^a   Rybak, Michael J ^c   Kullar, Ravina ^d   Dhand, Abhay ^e   Rose, Warren E ^f   Goff, Debra A ^g   Bressler, Adam M ^h   Lee, Yuman ⁱ   Pogliano, Joseph ^a   Johns, Scott ^j   Kaatz, Glenn W ^c   Ebright, John R ^c   Nizet, Victor ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^h DeKalb Medical Center   (United States)

ⁱ MAIMONIDES MEDICAL CENTER   (United States)

^j VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

more..

Author keywords

ceftaroline; daptomycin; MRSA; MRSE bacteremia; MSSA ; VISA

Indexed keywords

CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAROLINE; DAPTOMYCIN; NAFCILLIN; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL VIRULENCE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS EPIDERMIDIS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL; PERSISTENT INFECTION; SALVAGE THERAPY; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ANIMAL; BACTEREMIA; COMBINATION DRUG THERAPY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MIDDLE AGED; MOUSE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTEREMIA; CEPHALOSPORINS; DAPTOMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; SALVAGE THERAPY; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 84908310810     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.05.061     Document Type: Article

References (29)

1. C.K. Naber Staphylococcus aureus bacteremia: epidemiology, pathophysiology, and management strategies Clin Infect Dis 48 2009 231 237
2. V.G. Fowler Jr, M.K. Olsen, and G.R. Corey Clinical identifiers of complicated Staphylococcus aureus bacteremia Arch Intern Med 163 2003 2066 2072
3. G. Sakoulas, G.M. Eliopoulos, and V.G. Fowler Jr Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlate with defective autolysis and loss of accessory gene regulator (agr) function Antimicrob Agents Chemother 49 2005 2687 2692
4. N.N. Mishra, A.S. Bayer, P.A. Moise, and G. Sakoulas Reduced susceptibility to host defense cationic peptides and daptomycin co-emerge in MRSA from daptomycin-naive bacteremic patients J Infect Dis 206 2012 1160 1167
5. A. Dhand, A.S. Bayer, and J. Pogliano Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of daptomycin binding Clin Infect Dis 53 2011 158 163
6. A. Berti, J. Wergin, and G. Girdaukas Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combination with other antibiotics Antimicrob Agents Chemother 56 2012 5046 5053
7. Forest Laboratories, Inc. Ceftaroline fosamil package insert. http://www.accessdata.fda.gov/drugsatfdadocs/label/2010/200327s000lbl.pdf. Accessed October 10, 2012.
8. B.J. Werth, C. Vidaillac, and K.P. Murray Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA Antimicrob Agents Chemother 57 2013 2376 2379
9. W.E. Rose, L.T. Schultz, and D. Andes Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity Antimicrob Agents Chemother 56 2012 5296 5302
10. Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA). NRS71. http://www.narsa.net/control/member/viewisolatedetails?repositoryId=104&isolateId=71. Accessed October 10, 2012.
11. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Document M7-A7. Wayne, Pa: Clinical and Laboratory Standards Institute, 2006.
12. G. Sakoulas, A.S. Bayer, and J. Pogliano Ampicillin enhances daptomycin- and cationic host defense peptide-mediate killing of ampicillin and vancomycin-resistant Enterococcus faecium Antimicrob Agents Chemother 56 2012 838 844
13. R.M. Humphries, T. Kelesidis, and R. Tewhey Genotypic and phenotypic evaluation of the evolution of high-level daptomycin non-susceptibility in vancomycin-resistant Enterococcus faecium Antimicrob Agents Chemother 56 2012 6051 6053
14. S.A. Kristian, V. Datta, and C. Weidenmaier D-alanylation of teichoic acids promotes Group A streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion J Bacteriol 187 2005 6719 6725
15. M. von Köckritz-Blickwede, O.A. Chow, and V. Nizet Fetal calf serum contains heat-stable nucleases that degrade neutrophil extracellular traps Blood 114 2009 5245 5246
16. C.R. Diaz, J.G. Kane, R.H. Parker, and F.R. Pelsor Pharmacokinetics of nafcillin in patients with renal failure Antimicrob Agents Chemother 12 1977 98 101
17. Daptomycin [package insert]. Lexington, Mass: Cubist Pharmaceuticals; August 2008.
18. P.G. Charles, P.B. Ward, and P.D. Johnson Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus Clin Infect Dis 38 2004 448 451
19. B.T. Tsuji, M.J. Rybak, K.L. Lau, and G. Sakoulas Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus (VISA) Antimicrob Agents Chemother 51 2007 1089 1091
20. N.N. Mishra, S.J. Yang, and L. Chen Emergence of daptomycin resistance in daptomycin-naïve rabbits with methicillin-resistant Staphylococcus aureus prosthetic joint infection is associated with resistance to host defense cationic peptides and mprF polymorphisms PLoS ONE 8 2013 e71151
21. K.H. Rand, and H.J. Houck Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 48 2004 2871 2875
22. D.R. Snydman, L.A. McDermott, and N.V. Jacobus Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves J Chemother 17 2005 614 621
23. H. Komatsuzawa, J. Suzuki, and M. Sugai Effect of combination of oxacillin and non-beta-lactam antibiotics on methicillin-resistant Staphylococcus aureus J Antimicrob Chemother 33 1994 1155 1163
24. S. Mehta, C. Singh, and P.K. Chanda Beta-lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAP-resistant derivatives Antimicrob Agents Chemother 56 2012 6192 6200
25. S.J. Yang, Y.Q. Xiong, and S. Boyle-Vavra Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect") Antimicrob Agents Chemother 54 2010 3161 3169
26. Paladino JA, Shields RK, Taylor JE, Schentag JJ. Abstr Intersci Conf Antimicrob. Agents Chemother. 2013; abstract K-709. Available at: http://www.icaaconline.com/php/icaac2013abstracts/start.htm.
27. H.M. Polenakovic, and C.M. Pleiman Ceftaroline for methicillin-resistant Staphylococcus aureus bacteremia: case series and review of the literature Int J Antimicrob Agents 42 2013 450 455
28. A. Berti, G. Sakoulas, and V. Nizet β-lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 57 2013 5005 5012
29. K. Kosowska-Shick, P.L. McGhee, and P.C. Appelbaum Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae Antimicrob Agents Chemother 54 2010 1670 1677